Skip to main content
Equibles
PHAT logo

PHAT · Phathom Pharmaceuticals, Inc.

Track PHAT — free

Use PHAT with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$9.50 +0.45 (+4.97%) At close · Sep 4
Russell 2000 member Rebalance outlook locked
Market Cap
$768.56M
Shares
80.90M

PHAT metrics

66 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$9.50
Market cap
$768.56M

Price action

19 metrics
Price change (1W)
+3.5%
Price change (30D)
+10.9%
Price change (3M)
-6.2%
Price change (6M)
-11.0%
Price change (YTD)
-42.7%
Price change (1Y)
-20.8%
Trailing year
Price change (5Y)
-73.6%
52-week high
$18.08
52-week low
$8.23
Change from 52-week high
-47.5%
Change from 52-week low
+15.4%
Annualized volatility
64.1%
Beta
0.5
RSI (14D)
51.9
Price vs SMA 50
-5.5%
Price vs SMA 200
-21.3%
Avg volume (3M)
1.25M
Relative volume
1.0
Average dollar volume
$12.45M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
80.90M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
3.1×
reciprocal yield 31.9%
EV / EBITDA
—
EV / EBIT
—
P / sales
3.2×
reciprocal yield 31.2%
P / book
—
FCF yield
-4.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-12.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
29.9×
reciprocal yield 3.3%
EV / revenue historical average (5Y)
29.9×
reciprocal yield 3.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-30

Profitability

9 metrics
Gross margin
82.9%
Operating margin
-17.0%
Trailing 12 months
Net margin
-41.3%
Gross profit (TTM)
$198.73M
Operating profit (TTM)
−$40.64M
Net income (TTM)
−$99.07M
Trailing 12 months
Diluted EPS (TTM)
$-1.25
FCF margin
-15.4%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.19

Growth

11 metrics
Revenue growth YoY
+88.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$239.66M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+15.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-30.3%
Debt / equity
—
Current ratio
1.9
EBITDA (TTM)
−$40.13M
Free cash flow (TTM)
−$36.91M
Quick ratio
1.9
Interest coverage
-0.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$17.89M
Latest balance sheet
Cash & equivalents
$182.48M
Total assets
$327.07M
Total debt
$164.59M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$36.69M
Capital expenditures (TTM)
$219,000
R&D (TTM)
$30.10M
SG&A (TTM)
$209.27M
Stock compensation (TTM)
$27.15M
R&D / revenue
12.6%
Stock compensation / revenue
11.3%

Ownership (13F)

3 metrics
13F filers
164
13F filer change QoQ
-12
Institutional ownership
90.4%

Short interest

3 metrics
Short interest
14.6%
Latest settlement · 6.9 days to cover
Days to cover
6.9d
Short-squeeze score
62 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1783183 CUSIP 71722W107 13F (30d) 120 filings 120 filers Visit website Investor relations